Proteome Sciences PLC Director/PDMR Shareholding (6389I)
March 22 2018 - 8:18AM
UK Regulatory
TIDMPRM
RNS Number : 6389I
Proteome Sciences PLC
22 March 2018
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company announces that on 21 March 2018 Roger McDowell, a
Non-Executive Director of the Company, sold 500,000 ordinary shares
of 1 pence each ("Ordinary Shares") at a price of 3 pence per
Ordinary Share and bought, into his SIPP, 500,000 Ordinary Shares
at a price of 3.006 pence per Ordinary Share (the "Transfer").
Following the Transfer, Mr McDowell's beneficial interest in the
Company remains at 2,500,000 Ordinary Shares representing
approximately 0.91% of the issued share capital of the Company.
For further information:
Proteome Sciences plc
Jeremy Haigh, Chief Executive Officer Tel: +44 (0)20 7043 2116
Ian Pike, Chief Scientific Officer
Stefan Fuhrman, Finance Director
finnCap Limited (Nominated Adviser/Broker)
Geoff Nash/James Thompson Tel: +44 (0)20 7220 0500
Tony Quirke (broking)
About Proteome Sciences plc. (www.proteomics.com):
Proteome Sciences is a leader in applied proteomics offering
high sensitivity, proprietary technologies and workflows for
mapping cell signalling pathways (SysQuant(R) ) and for the
discovery, validation and assay development of protein biomarkers
(TMTcalibrator(TM) ). The company has its headquarters in London,
UK, with laboratory facilities in Frankfurt, Germany from where the
PS Biomarker Services(TM) division provides outsourced proteomics
services and proprietary biomarker assays to biopharmaceutical and
diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein
biomarkers for diagnostic and treatment applications in important
areas of human therapeutics such as cancer, stroke and Alzheimer's
disease, and these are available for license.
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Roger McDowell
2. Reason for the Notification
a) Position/status Non-Executive Director
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Proteome Sciences plc
b) LEI 213800Q62ICXANKU2986
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Financial instrument, type of Ordinary Shares of 1p each
instrument
Identification code GB0003104196
b) Nature of the transaction Purchase and sale of shares
c) Price(s) and volume(s) 500,000 Ordinary Shares bought at 3.006p per Ordinary
Share
500,000 Ordinary Shares sold at 3.000p per Ordinary
Share
d) Aggregated information: 500,000 Ordinary Shares bought at 3.006p per Ordinary
-- Aggregated volume Share
-- Price 500,000 Ordinary Shares sold at 3.000p per Ordinary
Share
e) Date of the transaction 21 March 2018
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHSEMFDEFASEFD
(END) Dow Jones Newswires
March 22, 2018 09:18 ET (13:18 GMT)
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2024 to May 2024
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From May 2023 to May 2024